Catalyst Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 41.28% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 41.28% . Looking at the past 52 week period, the stock price is up at 37.5% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Catalyst Pharmaceuticals, Inc. has a positive value of 64.71 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 79.69.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has climbed 38.74% in the past week and advanced 33.91% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 38.41% and the outperformance has advanced to 32.39% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) : On Friday heightened volatility was witnessed in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) which led to swings in the share price. The stock opened for trading at $1.46 and hit $1.64 on the upside , eventually ending the session at $1.54, with a gain of 1.99% or 0.03 points. The heightened volatility saw the trading volume jump to 1,489,322 shares. The 52-week high of the share price is $1.77 and the company has a market cap of $128 million. The 52-week low of the share price is at $0.51 .
Company has reported several Insider transactions to the SEC, on Jul 12, 2016, Charles B Okeeffe (director) purchased 20,000 shares at 0.81 per share price.On Jun 14, 2016, Donald A Denkhaus (director) purchased 50,000 shares at 0.65 per share price.On Jun 14, 2016, Patrick J Mcenany (CEO) purchased 105,300 shares at 0.65 per share price.
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhavens patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhavens vigabatrin-related foreign patents or patents pending worldwide. The Companys initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.